Este sitio web utiliza cookies propias para ofrecer un mejor servicio. Si continúa navegando consideramos que acepta su uso. Encontrará más información en nuestra Política de Cookies.
OK | Más informaciónSolicitudes publicadas en los últimos 30 días / Applications published in the last 30 days
NºPublicación: US2023028293A1 26/01/2023
Solicitante:
SHERBENOU DANIEL [US]
WALKER ZACHARY [US]
IDLER BEAU [US]
UNIV COLORADO REGENTS [US]
Resumen de: US2023028293A1
Multiple myeloma (MM) combination therapies based on protein translation inhibitors, immunomodulators, and bromodomain extra-terminal inhibitors. Methods are provided for treating multiple myeloma in a subject, including administering a therapeutically effective amount of at least one protein translation inhibitor and a therapeutically effective amount of at least one immunomodulatory drug (IMiD), administering a therapeutically effective amount of at least one protein translation inhibitor and a therapeutically effective amount of at least one BET inhibitor, and/or administering a therapeutically effective amount of at least one IMiD and a therapeutically effective amount of at least one BET inhibitor.
NºPublicación: US2023027993A1 26/01/2023
Solicitante:
AUTOLUS LTD [GB]
Resumen de: US2023027993A1
The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.
NºPublicación: US2023023124A1 26/01/2023
Solicitante:
REMEDY PLAN INC [US]
Resumen de: US2023023124A1
Disclosed are compounds, methods, compositions, uses, and kits that allow for treating cancer. In some embodiments, the compounds are used to treat diseases or disorders. The compounds may treat cancer by targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, lymphoma, liver cancer, endometrial cancer, leukemia, or multiple myeloma. Disclosed are compounds, methods, compositions, uses, and kits that may be used in regenerative medicine. The compounds utilized in the disclosure are of Formula (0) and (I).
NºPublicación: US2023022917A1 26/01/2023
Solicitante:
MODERN BIOSCIENCES LTD [GB]
Resumen de: US2023022917A1
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds of the following formula (collectively referred to herein as NASMP compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, e.g., multiple myeloma, diffuse large B-cell lymphoma, acute myeloid leukemia, eosinophilic leukemia, glioblastoma, melanoma, ovarian cancer, chemotherapy resistant cancer, radiation resistant cancer, inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, psoriasis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus (SLE), lupus nephritis, asthma, chronic obstructive pulmonary disease (COPD), Hidradenitis suppurativa, autoimmune hepatitis, etc. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.
NºPublicación: US2023022956A1 26/01/2023
Solicitante:
GLAXOSMITHKLINE BIOLOGICALS SA [BE]
VARIATION BIOTECHNOLOGIES INC [CA]
Resumen de: US2023022956A1
The present disclosure provides compositions and methods useful for treating Glioblastoma Multiforme (GBM) which comprise virus-like particles (VLPs) comprising murine leukemia virus (MLV) core proteins and the human cytomegalovirus epitopes, gB and pp65, formulated with an adjuvant comprising a saponin and a TLR4 agonist.
NºPublicación: US2023029187A1 26/01/2023
Solicitante:
SOUTHERN RES INST [US]
Resumen de: US2023029187A1
The present disclosure is concerned with dipeptide compounds for the treatment of various cancers such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, bladder cancer, thyroid cancer, testicular cancer, pancreatic cancer, endometrial cancer, melanomas, gliomas, leukemias, lymphomas, chronic myeloproliferative disorders, myelodysplastic syndromes, myeloproliferative neoplasms, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
NºPublicación: US2023028058A1 26/01/2023
Solicitante:
OHIO STATE INNOVATION FOUNDATION [US]
Resumen de: US2023028058A1
A system and method for accurate determination of sequence variants from noisy sequencing data, including single nucleotide variants and structural variants of the internal tandem duplication type. This system expands the utility of inexpensive sequencing instruments which stream relatively high-error output sequences in real time, such that they may be used in high-stakes contexts, such as clinical cancer care. An example application is Acute Myeloid Leukemia (AML), where healthcare providers may need to make decisions in hours, is provided.
NºPublicación: US2023027198A1 26/01/2023
Solicitante:
UNIV ROCKEFELLER [US]
BRIDGE MEDICINES LLC [US]
Resumen de: US2023027198A1
Methods and compositions for treating leukemia are disclosed. Acylated 6-aminoindoles, acylated 6-aminopyrrolopyridines and acylated 3-aminopyrrolo[3,2-c]pyridazines of the following formulainhibit ENL/AF9 YEATS and are therefore useful for treating leukemia.
NºPublicación: US2023027184A1 26/01/2023
Solicitante:
GENENTECH INC [US]
ABBVIE INC [US]
Resumen de: US2023027184A1
Provided herein are methods for treating acute myeloid leukemia (AML) in a patient with cytopenia when on a combination therapy of venetoclax and azacitidine. Also provided herein are methods of managing a cytopenia in such patient.
NºPublicación: US2023027088A1 26/01/2023
Solicitante:
HINOVA PHARMACEUTICALS INC [CN]
Resumen de: US2023027088A1
An EP300/CBP inhibitor, specifically provided is a compound as shown in formula I, or a deuterated product thereof, or a salt thereof, or a conformational isomer thereof, or a crystal form thereof, or a solvate thereof. The compound is highly selective for EP300/CBP, and can effectively inhibit the activity of EP300/CBP; in addition, the compound has an excellent inhibitory effect on various tumor cells including prostate cancer cells, leukemia cells, breast cancer cells and multiple myeloma cells. The compound has broad application prospects in the preparation of an EP300/CBP inhibitor, and drugs for preventing and/or treating tumors, myeloid hematopoietic stem/progenitor cells malignant disease, and regulating regulatory T cells.
NºPublicación: US2023026111A1 26/01/2023
Solicitante:
AUTOLUS LTD [GB]
Resumen de: US2023026111A1
The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.
NºPublicación: WO2023002362A1 26/01/2023
Solicitante:
PFIZER [US]
Resumen de: WO2023002362A1
This invention relates to therapies useful for the treatment of hematological malignancies. In particular the invention relates to a method of treating acute myeloid leukemia (AML) in a patient in need thereof, wherein said patient is positive for at least one mutation of the FLT3 gene, said method comprising administering to said patient a smoothened inhibitor, or a pharmaceutically acceptable salt thereof, in combination with azacitidine, thereby treating said acute myeloid leukemia. The invention also relates to associated combination therapies, pharmaceutical compositions, pharmaceutical uses and kits.
NºPublicación: WO2023001774A1 26/01/2023
Solicitante:
CELYAD ONCOLOGY S A [BE]
Resumen de: WO2023001774A1
The present application relates to the field of immunotherapy, more particularly to the field of adoptive cell therapy (ACT). Here, NKG2D CAR expressing cells that also express IL-18 are proposed. Also proposed are polynucleotides, vectors encoding the NKG2D CAR and IL-18 and cells expressing both. These cells are particularly suitable for use in immunotherapy, including allogeneic therapy. The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. Further, strategies to treat diseases such as cancer using these cells are also provided. The engineered immune cells, such as T-cells or natural killer (NK) cells, expressing such CARs are suitable for treating lymphomas, multiple myeloma and leukemia, but other tumors can be treated as well, depending on the specificity of the CAR. Most notably, as expression and secretion of the pro-inflammatory cytokine I L-18 is beneficial to reducing the immunosuppressive effect of the tumor microenvironment, treatment of solid tumors is envisaged.
NºPublicación: WO2023001942A1 26/01/2023
Solicitante:
RAPPOSELLI SIMONA [IT]
GAUDIO EUGENIO [CH]
DAL PIAZ FABRIZIO [IT]
Resumen de: WO2023001942A1
The invention relates to a 2-oxoindole compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are, independently from each other, hydrogen,1H-imidazolyl, thienyl and 1-methyl-1H-imidazolyl, 2-methyl-1H-imidazolyl,2-aminopyridinyl, 1H-pyrazolyl, with the proviso that one of R1 and R2 is hydrogen; or R1 and R2 together form 9H-fluorene R3 is hydrogen, (C1-C3)alkyl, halogen or NO2; for use as a 14-3-3 protein modulator of a tumor selected from the group consisting of a lymphoma, chronic lymphocytic leukaemia (CLL), Ewing sarcoma, colon cancer, melanoma and anaplastic thyroid cancer (ATC). The invention relates also new 2-oxoindole compound of Formula (I) or a pharmaceutically acceptable salt thereof..
NºPublicación: WO2023000708A1 26/01/2023
Solicitante:
UNIV CHINA PHARMA [CN]
Resumen de: WO2023000708A1
Disclosed are a polysubstituted purine compound as shown in formula (I), and a pharmaceutically acceptable salt thereof, a preparation method therefor and the use thereof. Also disclosed is that the compound has an obvious inhibitory effect on RNA adenosine deaminase 1 (ADAR1) and can be used for preventing and/or treating cancer or tumor-related diseases caused by abnormal activity of such enzymes, especially prostate cancer, leukemia, breast cancer, multiple myeloma, lung cancer, stomach cancer, ovarian cancer, colon cancer, liver cancer, pancreatic cancer, human glioma and other diseases.
NºPublicación: WO2023004283A1 26/01/2023
Solicitante:
DANA FARBER CANCER INST INC [US]
Resumen de: WO2023004283A1
Disclosed is a method of treating cancer with a compound that possesses degradation activity against SMARCA4/2 in combination with a DOT1L r inhibitor.
NºPublicación: WO2023003862A1 26/01/2023
Solicitante:
UNIV EMORY [US]
Resumen de: WO2023003862A1
CXCR4 antagonists and pharmaceutical formulations thereof are disclosed. The compounds and pharmaceutical formulations disclosed herein can be used to antagonize the CXCR4 pathway for mobilizing stem cells or treating a condition, disorder, or disease associated with the CXCR4 pathway. Exemplary conditions, disorders, and diseases relevant to this disclosure include HIV infections, WHIM syndrome, Waldenström macroglobulinemia, chronic neutropenia, primary immune-deficiency, aplastic anemia, hypoplastic myelodysplastic syndrome, acute respiratory distress syndrome (ARDS), ankylosing spondylitis, autoimmune diseases, and cancers.
NºPublicación: US2023024050A1 26/01/2023
Solicitante:
SOLIGENIX INC [US]
Resumen de: US2023024050A1
A method of treating CTCL comprising applying a combination of an effective amount of hypericin together with a form of visible light photodynamic therapy. Preferably, the effective amount of hypericin is an ointment comprising less than 1% hypericin. More preferably, the form of photodynamic therapy comprises an administration of escalating doses of visible light. Optionally, the escalating doses of visible light starts at about 5 J/cm2 and increases to a maximum dose of about 12 J/cm2.
NºPublicación: US2023022417A1 26/01/2023
Solicitante:
LIQUID BIOPSY RES LLC [KN]
Resumen de: US2023022417A1
The present invention is directed to methods for detecting a plasma cell dyscrasia like myeloma or MGUS, methods for determining whether a plasma cell dyscrasiais stable or progressive, methods for determining a risk for disease relapse, and methods for determining a response by a subject having a plasma cell dyscrasia to a therapy.
NºPublicación: US2023021548A1 26/01/2023
Solicitante:
AUTOLUS LTD [GB]
Resumen de: US2023021548A1
The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.
NºPublicación: US2023028910A1 26/01/2023
Solicitante:
SCAILYTE AG [CH]
UNIV ZUERICH [CH]
Resumen de: US2023028910A1
The present invention relates to a method for diagnosing Sézary syndrome or mycosis fungoides in a subject. The present invention further relates to a method for determining the frequency of Sézary signature cells and/or mycosis fungoides cells in a sample. Further, the present invention relates to a computer-implemented method comprising a classifier algorithm to determine the frequency of Sézary signature cells and/or mycosis fungoides cells. In addition the present invention relates to a panel of biomarkers that can be used for the diagnosis of Sézary syndrome or mycosis fungoides.
NºPublicación: EP4121430A1 25/01/2023
Solicitante:
FLASH THERAPEUTTICS LLC [US]
Resumen de: WO2021184154A1
Provided herein are compounds for treating acute myeloid leukemia or inhibiting recurrence of acute myeloid leukemia and for inhibiting growth of and/or killing leukemic stem cells.
NºPublicación: EP4122494A1 25/01/2023
Solicitante:
MANDOM CORP [JP]
UNIV OSAKA [JP]
UNIV NAGOYA CITY PUBLIC UNIV CORP [JP]
Resumen de: EP4122494A1
The present invention provides a novel method for detecting an indicator of T cell lymphoma. The method for detecting an indicator of T cell lymphoma includes the step of detecting acetylated tubulin in a T cell that has been collected from a subject.
NºPublicación: EP4122928A1 25/01/2023
Solicitante:
SHENZHEN TARGETRX INC [CN]
Resumen de: EP4122928A1
Provided are a crystal form of a free base or a pharmaceutically acceptable salt of (R)-N-(4-(chlorodifluoromethoxy)phenyl)-6-(3-fluoropyrrolidin-1-yl)-5-(pyrazin-2-yl)nicotinamide (compound A), a preparation method therefor, and use of the compound in preparation of drugs for treating diseases mediated by Bcr-Abl kinase and mutants thereof, such as chronic granulocytic leukemia. Also provided are a method for preparing compound A, and a preparation containing compound A.
Nº publicación: EP4121051A1 25/01/2023
Solicitante:
CELGENE CORP [US]
Resumen de: WO2021188387A1
Provided herein are methods of treatment of AML comprising administering 2-(4- chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)methyl)-2,2- difluoroacetamide or a stereoisomer or mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a combination therapy.